ECT204
Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2Active
Key Facts
Indication
Advanced Hepatocellular Carcinoma (HCC)
Phase
Phase 1/2
Status
Active
Company
About Eureka Therapeutics
Eureka Therapeutics is a private, clinical-stage biotech company headquartered in Emeryville, California, founded in 2006. The company is advancing a pipeline of T-cell therapies for solid tumors, anchored by its two core technology platforms: the ARTEMIS T-cell receptor platform and the E-ALPHA antibody discovery platform. A key program, ECT204 for hepatocellular carcinoma, has received FDA RMAT designation, indicating significant regulatory recognition. Eureka's strategy focuses on overcoming the challenges of treating solid tumors with cell therapy, a major unmet need in oncology.
View full company profileTherapeutic Areas
Other Advanced Hepatocellular Carcinoma (HCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| TheraBionic P1 | TheraBionic | Approved/Commercial |